Effect of Extending the Original Eligibility Criteria for the “CROSS” Neoadjuvant Chemoradiotherapy on Toxicity and Survival in Esophageal Cancer.

Journal of Clinical Oncology - United States
doi 10.1200/jco.2017.35.4_suppl.187
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Society of Clinical Oncology (ASCO)

Related search

Intensified Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer in Elderly Patients: Toxicity, Disease Control, and Survival Outcomes

Clinical Colorectal Cancer
OncologyGastroenterology
2018English

Chemoradiotherapy for Esophageal Cancer

The Korean Journal of Helicobacter and Upper Gastrointestinal Research
2019English

ASO Author Reflections: Intensified Neoadjuvant Chemoradiotherapy Followed by Esophagectomy in Esophageal Cancer

Annals of Surgical Oncology
OncologySurgery
2020English

Neoadjuvant Twice Daily Chemoradiotherapy for Esophageal Cancer: Treatment-Related Mortality and Long-Term Outcomes

Advances in Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2017English

Neoadjuvant Chemoradiotherapy in Rectal Cancer

Memo - Magazine of European Medical Oncology
OncologyHematology
2020English

Prognostic Significance of Lung Radiation Dose in Patients With Esophageal Cancer Treated With Neoadjuvant Chemoradiotherapy

Radiation Oncology
Nuclear MedicineRadiologyImagingOncology
2019English

Preoperative Chemoradiotherapy in Locally Advanced Esophageal Cancer

Acta chirurgica iugoslavica
2009English

Single Nucleotide Polymorphism TGFβ1 R25P Correlates With Acute Toxicity During Neoadjuvant Chemoradiotherapy in Rectal Cancer Patients

International Journal of Radiation Oncology Biology Physics
OncologyRadiologyCancer ResearchRadiationNuclear MedicineImaging
2017English

Neoadjuvant Therapy for Esophageal Cancer: Who, When, and What?

Cancer
Cancer ResearchOncology
2018English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2025 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy